company news  relmada therapeutics inc rlmd company news news  events home news  events company news news  events company news please check back soon for updates relmada therapeutics inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report relmada therapeutics inc  product pipeline review   published by global markets direct product code  published october   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license relmada therapeutics inc  product pipeline review   published october   content info  pages description summary global markets directs relmada therapeutics inc  product pipeline review   provides an overview of the relmada therapeutics incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of relmada therapeutics incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of relmada therapeutics inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of relmada therapeutics incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the relmada therapeutics incs pipeline products reasons to buy evaluate relmada therapeutics incs strategic position with total access to detailed information on its product pipeline assess the growth potential of relmada therapeutics inc in its therapy areas of focus identify new drug targets and therapeutic classes in the relmada therapeutics incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of relmada therapeutics inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of relmada therapeutics inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of relmada therapeutics inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures relmada therapeutics inc snapshot relmada therapeutics inc overview key information key facts relmada therapeutics inc  research and development overview key therapeutic areas relmada therapeutics inc  pipeline review pipeline products by stage of development pipeline products  monotherapy relmada therapeutics inc  pipeline products glance relmada therapeutics inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities relmada therapeutics inc  early stage pipeline products preclinical productscombination treatment modalities relmada therapeutics inc  drug profiles levorphanol tartrate er product description mechanism of action rd progress buprenorphine hydrochloride er product description mechanism of action rd progress rel product description mechanism of action rd progress mepivacaine hydrochloride product description mechanism of action rd progress relmada therapeutics inc  pipeline analysis relmada therapeutics inc  pipeline products by target relmada therapeutics inc  pipeline products by route of administration relmada therapeutics inc  pipeline products by molecule type relmada therapeutics inc  pipeline products by mechanism of action relmada therapeutics inc  recent pipeline updates relmada therapeutics inc  dormant projects relmada therapeutics inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables relmada therapeutics inc key information relmada therapeutics inc key facts relmada therapeutics inc  pipeline by indication  relmada therapeutics inc  pipeline by stage of development  relmada therapeutics inc  monotherapy products in pipeline  relmada therapeutics inc  phase ii  relmada therapeutics inc  phase i  relmada therapeutics inc  preclinical  relmada therapeutics inc  pipeline by target  relmada therapeutics inc  pipeline by route of administration  relmada therapeutics inc  pipeline by molecule type  relmada therapeutics inc  pipeline products by mechanism of action  relmada therapeutics inc  recent pipeline updates  relmada therapeutics inc  dormant developmental projects list of figures relmada therapeutics inc  pipeline by top  indication  relmada therapeutics inc  pipeline by stage of development  relmada therapeutics inc  monotherapy products in pipeline  relmada therapeutics inc  pipeline by top  target  relmada therapeutics inc  pipeline by top  route of administration  relmada therapeutics inc  pipeline by top  molecule type  relmada therapeutics inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved media resources  relmada therapeutics inc rlmd media resources news  events home news  events media resources news  events media resources about the company product pipeline management team investor relations investor overview press releases relmada therapeutics inc rlmd built on innovations in central nervous system cns diseases relmada therapeutics addresses unmet needs in central nervous system cns diseases  depression and chronic pain who we are relmada therapeutics inc is a clinical stage publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system cns diseases learn more about relmada therapeutics our drug candidates rel dmethadone novel nmda receptor antagonist being developed for the treatment of depression and neuropathic pain view rel dmethadone our drug candidates rel levocap er extended release abuse resistant form of broad spectrum opioid levorphanol for treatment of chronic pain when an opioid is needed view rel levocap er our drug candidates rel butab novel oral formulations of modified release buprenorphine being developed for both chronic pain and opioid dependence indications view rel butab our drug candidates rel mepigel topical gel dosage form of local anesthetic mepivacaine for treatment of postherpetic neuralgia phn and hivassociated neuropathy view rel mepigel our leadership our efforts are guided by highly experienced drug development leadership and worldclass scientific advisors that provide the expertise to efficiently advance product development meet our management team meet our board of directors meet our scientific and business advisors latest news jun   relmada therapeutics appoints dr maurizio fava as chair of the dextromethadone scientific advisory board for its depression program see all news recent event february  february   nd annual disruptive growth  healthcare conference see all events twitter feed february    pm relmada therapeutics rlmd to participate in bio ceo  investor conference on tue feb   am et in conrad rm httpstcomkzhyeynbg see all tweets stock information relmada therapeutics inc otcqb rlmd volume day lowhigh  week lowhigh investor information download investor presentation view sec filings view investor relations product candidates  relmada therapeutics inc rlmd product candidates developing products for the treatment of central nervous system cns diseases product pipeline candidateregulatory path indication development stage rel dmethadonenew molecular entity novel nmda antagonist for the treatment of depression and neuropathic pain preclinical phase  phase  phase  preclinical phase  phase  phase  rel levocap erb regulatory path extended release abuse resistant form of broad spectrum opioid levorphanol preclinical phase  phase  phase  preclinical phase  phase  phase  rel butabb regulatory path first traditional oral tablet form of buprenorphine preclinical phase  phase  phase  preclinical phase  phase  phase  rel mepigelb regulatory path topical gel dosage form of local anesthetic mepivacaine preclinical phase  phase  phase  preclinical phase  phase  phase  projected stage of development in  months our drug candidates rel dmethadone novel nmda receptor antagonist being developed for the treatment of depression and neuropathic pain view rel dmethadone our drug candidates rel levocap er extended release abuse resistant form of broad spectrum opioid levorphanol for treatment of chronic pain when an opioid is needed view rel levocap er our drug candidates rel butab novel oral formulations of modified release buprenorphine being developed for both chronic pain and opioid dependence indications view rel butab our drug candidates rel mepigel topical gel dosage form of local anesthetic mepivacaine for treatment of postherpetic neuralgia phn and hivassociated neuropathy view rel mepigel pain treatment market pain market characteristics largest prescription drug market in the world   million rxs in us in  affects  billion people worldwide most frequent reason for physician visits in the united states affects more americans than diabetes heart disease and cancer combined us annual economic cost of health care due to pain is in excess of  billion an unsatisfied market better pain drugs are needed only  feel their pain is “under control” only  believe their pain medications are “very effective” the unmet medical need allows new pain drugs to expand the market rather than interfere with existing products greater demand exists for new extended release er products because of their limited availability in the market today relmada therapeutics inc rlmd built on innovations in central nervous system cns diseases relmada therapeutics addresses unmet needs in central nervous system cns diseases  depression and chronic pain who we are relmada therapeutics inc is a clinical stage publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system cns diseases learn more about relmada therapeutics our drug candidates rel dmethadone novel nmda receptor antagonist being developed for the treatment of depression and neuropathic pain view rel dmethadone our drug candidates rel levocap er extended release abuse resistant form of broad spectrum opioid levorphanol for treatment of chronic pain when an opioid is needed view rel levocap er our drug candidates rel butab novel oral formulations of modified release buprenorphine being developed for both chronic pain and opioid dependence indications view rel butab our drug candidates rel mepigel topical gel dosage form of local anesthetic mepivacaine for treatment of postherpetic neuralgia phn and hivassociated neuropathy view rel mepigel our leadership our efforts are guided by highly experienced drug development leadership and worldclass scientific advisors that provide the expertise to efficiently advance product development meet our management team meet our board of directors meet our scientific and business advisors latest news jun   relmada therapeutics appoints dr maurizio fava as chair of the dextromethadone scientific advisory board for its depression program see all news recent event february  february   nd annual disruptive growth  healthcare conference see all events twitter feed february    pm relmada therapeutics rlmd to participate in bio ceo  investor conference on tue feb   am et in conrad rm httpstcomkzhyeynbg see all tweets stock information relmada therapeutics inc otcqb rlmd volume day lowhigh  week lowhigh investor information download investor presentation view sec filings view investor relations governancecompliance  relmada therapeutics inc rlmd governancecompliance about relmada home about relmada governancecompliance about relmada governancecompliance name view document code of ethics and business conduct download code of ethics and business conduct audit committee charter download audit committee charter compensation committee charter download compensation committee charter publications  relmada therapeutics inc rlmd publications news  events home news  events publications news  events publications please check back soon for updates security check required facebookjoin or log into facebook   email or phonepasswordforgot accountlog indo you want to join facebooksign upsign upsecurity checkplease enter the text belowcant read the text abovetry another text or an audio captchatext in the boxwhats thissecurity checkthis is a standard security test that we use to prevent spammers from creating fake accounts and spamming userssubmitenglish usespañolfrançais franceالعربيةportuguês brasilitaliano한국어deutschहिन्दीmessengerfacebook litepeopleplacesgameslocationscelebritiesmarketplacegroupsrecipesmomentsinstagramaboutcreate adcreate pagedeveloperscareersprivacycookiesad choicestermssettingsactivity log facebook   product candidates  relmada therapeutics inc rlmd product candidates developing products for the treatment of central nervous system cns diseases product pipeline candidateregulatory path indication development stage rel dmethadonenew molecular entity novel nmda antagonist for the treatment of depression and neuropathic pain preclinical phase  phase  phase  preclinical phase  phase  phase  rel levocap erb regulatory path extended release abuse resistant form of broad spectrum opioid levorphanol preclinical phase  phase  phase  preclinical phase  phase  phase  rel butabb regulatory path first traditional oral tablet form of buprenorphine preclinical phase  phase  phase  preclinical phase  phase  phase  rel mepigelb regulatory path topical gel dosage form of local anesthetic mepivacaine preclinical phase  phase  phase  preclinical phase  phase  phase  projected stage of development in  months our drug candidates rel dmethadone novel nmda receptor antagonist being developed for the treatment of depression and neuropathic pain view rel dmethadone our drug candidates rel levocap er extended release abuse resistant form of broad spectrum opioid levorphanol for treatment of chronic pain when an opioid is needed view rel levocap er our drug candidates rel butab novel oral formulations of modified release buprenorphine being developed for both chronic pain and opioid dependence indications view rel butab our drug candidates rel mepigel topical gel dosage form of local anesthetic mepivacaine for treatment of postherpetic neuralgia phn and hivassociated neuropathy view rel mepigel pain treatment market pain market characteristics largest prescription drug market in the world   million rxs in us in  affects  billion people worldwide most frequent reason for physician visits in the united states affects more americans than diabetes heart disease and cancer combined us annual economic cost of health care due to pain is in excess of  billion an unsatisfied market better pain drugs are needed only  feel their pain is “under control” only  believe their pain medications are “very effective” the unmet medical need allows new pain drugs to expand the market rather than interfere with existing products greater demand exists for new extended release er products because of their limited availability in the market today stocks index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest astarbucks stock price target cut to  from  at jp morgan agoodyear tires stock dives after slashed profit outlook offsets inline earnings awatch out ‘kids’ are making the most money in this stock market astock market set to extend fresh tech rout as amazon disappoints gdp data ahead ashares of video game maker activision blizzard down more than  aintel earnings have message for amd and nvidia ‘bring it on’ aaarons shares up nearly  in friday premarket trading aamazon’s freespending ways hit earnings but don’t expect a shift to thrift aabbvie shares up  in premarket trade aabbvie still sees fullyear adj eps  to  aabbvie still sees fullyear eps  to  aabbvie q revenue  bln vs  bln factset consensus  bln aabbvie q adj eps  factset consensus  agoodyears stock plunges  premarket after q results aabbvie q eps  vs  cents agoodyear cuts  segment operating income outlook to  bln bln from  bln aget ready for the lessprofitable amazon that you used to know awells fargo charged customers for duplicate car insurance agoodyear q sales  bln vs  bln factset consensus  bln acorrect goodyear q adj eps  cents factset consensus  cents loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest agoodyear tires stock dives after slashed profit outlook offsets inline earnings awatch out ‘kids’ are making the most money in this stock market astock market set to extend fresh tech rout as amazon disappoints gdp data ahead ashares of video game maker activision blizzard down more than  aintel earnings have message for amd and nvidia ‘bring it on’ aaarons shares up nearly  in friday premarket trading aamazon’s freespending ways hit earnings but don’t expect a shift to thrift aabbvie shares up  in premarket trade aabbvie still sees fullyear adj eps  to  aabbvie still sees fullyear eps  to  aabbvie q revenue  bln vs  bln factset consensus  bln aabbvie q adj eps  factset consensus  agoodyears stock plunges  premarket after q results aabbvie q eps  vs  cents agoodyear cuts  segment operating income outlook to  bln bln from  bln aget ready for the lessprofitable amazon that you used to know awells fargo charged customers for duplicate car insurance agoodyear q sales  bln vs  bln factset consensus  bln acorrect goodyear q adj eps  cents factset consensus  cents agoodyear tire  rubber q eps  cents vs  cents a year ago loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest agoodyear tires stock dives after slashed profit outlook offsets inline earnings awatch out ‘kids’ are making the most money in this stock market astock market set to extend fresh tech rout as amazon disappoints gdp data ahead ashares of video game maker activision blizzard down more than  aintel earnings have message for amd and nvidia ‘bring it on’ aaarons shares up nearly  in friday premarket trading aamazon’s freespending ways hit earnings but don’t expect a shift to thrift aabbvie shares up  in premarket trade aabbvie still sees fullyear adj eps  to  aabbvie still sees fullyear eps  to  aabbvie q revenue  bln vs  bln factset consensus  bln aabbvie q adj eps  factset consensus  agoodyears stock plunges  premarket after q results aabbvie q eps  vs  cents agoodyear cuts  segment operating income outlook to  bln bln from  bln aget ready for the lessprofitable amazon that you used to know awells fargo charged customers for duplicate car insurance agoodyear q sales  bln vs  bln factset consensus  bln acorrect goodyear q adj eps  cents factset consensus  cents agoodyear tire  rubber q eps  cents vs  cents a year ago loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  rlmd key statistics  relmada therapeutics inc financial ratios  marketwatch bulletin investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close relmada therapeutics inc otc rlmd go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus relmada therapeutics inc market closed  quotes are delayed by  min jul    pm rlmd quoteszigmandelayed   change   volume volume  quotes are delayed by  min quoteszigmandelayed previous close     change   day low day high    week low  week high   company description relmada therapeutics inc is a clinicalstage and biotechnology company which engages in developing drug products together with new chemical entities that address areas of unmet medical need in the treatment of central nervous system diseases its portfolio of products include dmethadone levocap relmada therapeutics inc is a clinicalstage and biotechnology company which engages in developing drug products together with new chemical entities that address areas of unmet medical need in the treatment of central nervous system diseases its portfolio of products include dmethadone levocap er butab rel and mepigel rel the company was founded on may   and is headquartered in new york ny valuation pe current  pe ratio with extraordinary items  price to book ratio  enterprise value to ebitda  total debt to enterprise value  efficiency income per employee  liquidity current ratio  quick ratio  cash ratio  profitability return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  officers and executives name age officer since title dr sergio traversa   ceo cfo principal accounting officer  director mr michael d becker   senior vpfinance  corporate development mr charles j casamento   chairman mr paul kelly   independent director mr maged s shenouda   independent director insider actions – purchase – sale  – number of transactions  date name shares transaction value  shreeram n agharkar director    acquisition at  per share   shreeram n agharkar director    acquisition at  per share   shreeram n agharkar director    acquisition at  per share   sergio traversa chief executive officer director    acquisition at  per share   sergio traversa chief executive officer director    acquisition at  per share   sergio traversa chief executive officer director    acquisition at  per share   sergio traversa chief executive officer director    acquisition at  per share   sergio traversa chief executive officer director    acquisition at  per share   sergio traversa chief executive officer director    acquisition at  per share   sergio traversa chief executive officer director    acquisition at  per share   sergio traversa chief executive officer director    acquisition at  per share   sergio traversa chief executive officer director    acquisition at  per share   sandesh seth director    acquisition at  per share   sandesh seth director    acquisition at  per share   sandesh seth director    acquisition at  per share   sandesh seth director    acquisition at  per share   sandesh seth director    acquisition at  per share   maged s shenouda director    acquisition at  per share   maged s shenouda director    acquisition at  per share   maged s shenouda director    acquisition at  per share   sergio traversa chief executive officer director    acquisition at  per share   sandesh seth director    acquisition at  per share   sandesh seth director    acquisition at  per share   sandesh seth director    acquisition at  per share   sandesh seth director    acquisition at  per share   sandesh seth director    acquisition at  per share   sandesh seth director    acquisition at  per share   sandesh seth director    acquisition at  per share   paul kelly director    acquisition at  per share   paul kelly director    acquisition at  per share   paul kelly director    acquisition at  per share   paul kelly director    acquisition at  per share   paul kelly director    acquisition at  per share   paul kelly director    acquisition at  per share   maged s shenouda director    acquisition at  per share   charles j casamento director    acquisition at  per share   charles j casamento director    acquisition at  per share   charles j casamento director    acquisition at  per share   charles j casamento director    acquisition at  per share   charles j casamento director    acquisition at  per share  newslatestcompanyusrlmd marketwatch news on rlmd no news currently available for rlmd newsnonmarketwatchcompanyusrlmd other news on rlmd q relmada therapeutics inc  pm may    edgar online  edg  q k relmadas lead product candidate rel fast trackd for mdd shares ahead  premarket  am april    seeking alpha q relmada therapeutics inc  pm feb    edgar online  edg  q k q relmada therapeutics inc  pm nov    edgar online  edg  q k k relmada therapeutics inc  pm sept    edgar online  edg  q k court slaps injunction on relmada pursuers  am dec    seeking alpha relmada therapeutics sues former investment banker to block hostile takeover  pm dec    seeking alpha relmada gets big investment  a look at its pipeline  am nov    seeking alpha abuse resistance and oral reformulations bringing life to the opioid space  am oct    seeking alpha at a glance relmada therapeutics inc  third avenue th floor new york new york  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue na net income m employees  annual report for rlmd newspressreleasecompanyusrlmd press releases on rlmd relmada therapeutics appoints dr maurizio fava as chair of the dextromethadone scientific advisory board for its depression program  am june    pr newswire  prf dr ottavio vitolo appointed executive clinical advisor at relmada therapeutics  am june    pr newswire  prf charles j casamento appointed chairman of relmada therapeutics board of directors  am june    pr newswire  prf relmada therapeutics announces settlement of legal action with laidlaw  company  am may    pr newswire  prf relmada announces fda fast track designation for dmethadone for adjunctive treatment of major depressive disorder  am april    pr newswire  prf relmada therapeutics to participate in the nd annual disruptive growth  healthcare conference  am feb    pr newswire  prf relmada therapeutics to participate in bio ceo and investor conference  am feb    pr newswire  prf relmada announces fda acceptance of ind and authorization to commence phase a clinical trial for dmethadone  pm jan    pr newswire  prf relmada therapeutics to provide an update on the development plan for levocap er  pm jan    pr newswire  prf relmada therapeutics to present at biotech showcase   am jan    pr newswire  prf relmada therapeutics to present at ld micro main event investor conference  am nov    pr newswire  prf relmada therapeutics to present at the sidoti  company fall  emerging growth convention  am oct    pr newswire  prf relmada therapeutics announces issuance of key us patent covering dmethadone an nmda receptor antagonist for the treatment of depression and other psychiatric symptoms  am oct    pr newswire  prf relmada therapeutics to present at the th annual bio investor forum  am oct    pr newswire  prf relmada therapeutics chief scientific officer dr richard mangano to speak about dmethadone as a potential rapid acting antidepressant at neuro advance boston  am sept    pr newswire  prf relmada therapeutics to present at the ladenburg thalmann  healthcare conference  am sept    pr newswire  prf relmada therapeutics to present at the  aegis growth conference  am sept    pr newswire  prf relmada therapeutics files amended complaint against laidlaw and its principals matthew eitner and james ahern  am sept    pr newswire  prf pharmaceutical industry leader ronald m burch joins relmada therapeutics advisory team  am sept    pr newswire  prf relmada therapeutics to present at the rodman  renshaw th annual global investment conference  am sept    pr newswire  prf loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite tlt quoteszigmancomposite jnug x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest astarbucks stock price target cut to  from  at jp morgan agoodyear tires stock dives after slashed profit outlook offsets inline earnings awatch out ‘kids’ are making the most money in this stock market astock market set to extend fresh tech rout as amazon disappoints gdp data ahead ashares of video game maker activision blizzard down more than  aintel earnings have message for amd and nvidia ‘bring it on’ aaarons shares up nearly  in friday premarket trading aamazon’s freespending ways hit earnings but don’t expect a shift to thrift aabbvie shares up  in premarket trade aabbvie still sees fullyear adj eps  to  aabbvie still sees fullyear eps  to  aabbvie q revenue  bln vs  bln factset consensus  bln aabbvie q adj eps  factset consensus  agoodyears stock plunges  premarket after q results aabbvie q eps  vs  cents agoodyear cuts  segment operating income outlook to  bln bln from  bln aget ready for the lessprofitable amazon that you used to know awells fargo charged customers for duplicate car insurance agoodyear q sales  bln vs  bln factset consensus  bln acorrect goodyear q adj eps  cents factset consensus  cents loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one rlmd stock price  relmada therapeutics inc stock quote us otc  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y djia f    sp f    nasdaq f    gold    silver    crude oil    sp  movers adp  tsco  vz  orly  ca  jci  ffiv  xl  latest newsall times eastern a starbucks stock price target cut to  from  at jp morgan a goodyear tires stock dives after slashed profit outlook offsets inline earnings a opinion watch out ‘kids’ are making the most money in this stock market a updated stock market set to extend fresh tech rout as amazon disappoints gdp data ahead a shares of video game maker activision blizzard down more than  a updated intel earnings have message for amd and nvidia ‘bring it on’ a aarons shares up nearly  in friday premarket trading a updated amazon’s freespending ways hit earnings but don’t expect a shift to thrift a abbvie shares up  in premarket trade a abbvie still sees fullyear adj eps  to  to be replaced home investing quotes stocks united states rlmd overview compare quotes stock screener earnings calendar sectors rlmd us otc join td ameritrade find a broker relmada therapeutics inc watchlist createrlmdalert closed last updated jul    pm edt delayed quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta na rev per employee na pe ratio na eps  yield na dividend na exdividend date na short interest na na  of float shorted na average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones no headlines available up and down the ladder the latest comings and goings at jj merck and… dec   at  am et on the wall street journal recent news other news press releases q relmada therapeutics inc q relmada therapeutics inc may   at  pm et on edgar online  edg  q k relmadas lead product candidate rel fast trackd for mdd shares ahead  premarket apr   at  am et on seeking alpha q relmada therapeutics inc feb   at  pm et on edgar online  edg  q k q relmada therapeutics inc nov   at  pm et on edgar online  edg  q k k relmada therapeutics inc sep   at  pm et on edgar online  edg  q k court slaps injunction on relmada pursuers dec   at  am et on seeking alpha relmada therapeutics sues former investment banker to block hostile takeover dec   at  am et on seeking alpha relmada gets big investment  a look at its pipeline nov   at  pm et on seeking alpha abuse resistance and oral reformulations bringing life to the opioid space oct   at  am et on seeking alpha relmada therapeutics appoints dr maurizio fava as chair of the dextromethadone scientific advisory board for its depression program relmada therapeutics appoints dr maurizio fava as chair of the dextromethadone scientific advisory board for its depression program jun   at  am et on pr newswire  prf dr ottavio vitolo appointed executive clinical advisor at relmada therapeutics dr ottavio vitolo appointed executive clinical advisor at relmada therapeutics jun   at  am et on pr newswire  prf charles j casamento appointed chairman of relmada therapeutics board of directors charles j casamento appointed chairman of relmada therapeutics board of directors jun   at  am et on pr newswire  prf relmada therapeutics announces settlement of legal action with laidlaw  company relmada therapeutics announces settlement of legal action with laidlaw  company may   at  am et on pr newswire  prf relmada announces fda fast track designation for dmethadone for adjunctive treatment of major depressive disorder apr   at  am et on pr newswire  prf relmada therapeutics to participate in the nd annual disruptive growth  healthcare conference feb   at  am et on pr newswire  prf relmada therapeutics to participate in bio ceo and investor conference feb   at  am et on pr newswire  prf relmada announces fda acceptance of ind and authorization to commence phase a clinical trial for dmethadone jan   at  pm et on pr newswire  prf relmada therapeutics to provide an update on the development plan for levocap er jan   at  pm et on pr newswire  prf relmada therapeutics to present at biotech showcase  jan   at  am et on pr newswire  prf relmada therapeutics to present at ld micro main event investor conference nov   at  am et on pr newswire  prf relmada therapeutics to present at the sidoti  company fall  emerging growth convention oct   at  am et on pr newswire  prf relmada therapeutics announces issuance of key us patent covering dmethadone an nmda receptor antagonist for the treatment of depression and other psychiatric symptoms oct   at  am et on pr newswire  prf relmada therapeutics to present at the th annual bio investor forum oct   at  am et on pr newswire  prf relmada therapeutics chief scientific officer dr richard mangano to speak about dmethadone as a potential rapid acting antidepressant at neuro advance boston sep   at  am et on pr newswire  prf relmada therapeutics to present at the ladenburg thalmann  healthcare conference sep   at  am et on pr newswire  prf relmada therapeutics to present at the  aegis growth conference sep   at  am et on pr newswire  prf relmada therapeutics files amended complaint against laidlaw and its principals matthew eitner and james ahern sep   at  am et on pr newswire  prf pharmaceutical industry leader ronald m burch joins relmada therapeutics advisory team sep   at  am et on pr newswire  prf relmada therapeutics to present at the rodman  renshaw th annual global investment conference sep   at  am et on pr newswire  prf relmada therapeutics inc relmada therapeutics inc is a clinicalstage and biotechnology company which engages in developing drug products together with new chemical entities that address areas of unmet medical need in the treatment of central nervous system diseases its portfolio of products include dmethadone levocap er butab rel and mepigel rel the company was founded on may   and is headquartered in new york ny see full profile competitors name chg  market cap earth science tech inc  m nemus bioscience inc  m corgreen technologies holding corp  m cell source inc  m competitor data provided by partner content trending tickers powered by amzn  spy  uvxy  aapl  qqq  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft profile  relmada therapeutics inc rlmd profile investors home investors company information profile investors profile business description relmada therapeutics is a clinicalstage publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system cns diseases the company has a diversified portfolio of four products at various stages of development including dmethadone dextromethadone rel an nmethyldaspartate nmda receptor antagonist for depression and neuropathic pain levocap er rel an abuse resistant sustained release dosage form of the opioid analgesic levorphanol oral buprenorphine butab rel an oral dosage form of the opioid analgesic buprenorphine and topical mepivacaine mepigel rel an orphan drug designated topical formulation of the local anesthetic mepivacaine the companys product development efforts are guided by the internationally recognized scientific expertise of its research team the companys approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs company info address third avenueth floornew york ny  us telephone emailinforelmadacom industry classifications sectorhealthcare industrydrug manufacturers naicspharmaceutical preparation manufacturing  sicpharmaceutical preparations  investor relations  relmada therapeutics inc rlmd investor relations download investor presentation  million cash  equivalents as of   million net loss for three months ended   million common shares outstanding as of  home investors investor relations investors investor relations latest news jun   relmada therapeutics appoints dr maurizio fava as chair of the dextromethadone scientific advisory board for its depression program view press release sign up for email alerts be the first to receive breaking news sign up today latest financial results q  quarterly results dec   pdf html q filing html financials zip xls html xbrl stock information relmada therapeutics otcqb rlmd price change market cap volume  week lowhigh day lowhigh company overview download relmada therapeutics is a clinicalstage publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system cns diseases the company has a diversified portfolio of four products at various stages of development including dmethadone dextromethadone rel an nmethyldaspartate nmda receptor antagonist for depression and neuropathic pain levocap er rel an abuse resistant sustained release dosage form of the opioid analgesic levorphanol oral buprenorphine butab rel an oral dosage form of the opioid analgesic buprenorphine and topical mepivacaine mepigel rel an orphan drug designated topical formulation of the local anesthetic mepivacaine the companys product development efforts are guided by the internationally recognized scientific expertise of its research team the companys approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs officers  directors executive leadership board of directors scientific and business advisors sergio traversa pharmd mba chief executive officer and interim chief financial officer before joining relmada dr traversa was the cofounder and ceo of medeor inc a spinoff pharmaceutical company from cornell university dr traversa has over twentyfive years of experience in the healthcare sector in the united states… view full bio charles j casamento mba chairman of the board since  mr casamento has been executive director and principal of the sage group a health care advisory group  he was president and ceo of osteologix from october  until april  mr casamento was the founder of questcor… view full bio paul kelly mba director paul kelly has been actively involved as an analyst consultant and investor in the biotechnology sector for the past twenty years he began as an equity analyst at mabon securities in  and later served in the same capacity at ubs… view full bio maged shenouda rph mba director mr shenouda has over  years of biotechnology and equity research experience most recently he was head of business development and licensing at retrophin inc from january  to november  from january  to september  he… view full bio sergio traversa pharmd mba chief executive officer and interim chief financial officer before joining relmada dr traversa was the cofounder and ceo of medeor inc a spinoff pharmaceutical company from cornell university dr traversa has over twentyfive years of experience in the healthcare sector in the united states… view full bio gavril pasternak md phd dr gavril pasternak holds the anne burnett tandy chair in neurology at memorial sloankettering cancer center and is a laboratory head in the molecular pharmacology and chemistry program within the sloankettering institute after… view full bio andrew rice md frca dr andrew rice is professor of pain research at imperial college and an hon consultant in pain medicine at chelsea and westminster hospital providing a service for patients with neuropathic pain  he qualified in medicine at st… view full bio robert h dworkin phd dr robert h dworkin received his ba in  from the university of pennsylvania and his phd in  from harvard university he is currently professor of anesthesiology neurology oncology and psychiatry professor of neurology in… view full bio michael e thase md dr michael e thase joined the faculty of the perelman school of medicine at the university of pennsylvania in  as professor of psychiatry after more than  years at the university of pittsburgh medical center and the western… view full bio james dolan mba james dolan is an experienced biopharmaceutical executive with more than  years of pharmabiotech industry experience including in the areas of global finance strategic planning pharmaceutical marketing and business development mr… view full bio relmada therapeutics inc private company information  bloomberg july    am et pharmaceuticals company overview of relmada therapeutics inc snapshot people company overview relmada therapeutics inc a clinical stage biotechnology company focuses on developing drugs to treat central nervous system cns diseases primarily depression and chronic pain in the united states its lead product candidate dmethadone is being developed as a rapidly acting oral agent for the treatment of depression neuropathic pain andor other potential cns pathological conditions the company is also developing include levocap er an extended release abuse deterrent proprietary formulation of the opioid analgesic levorphanol for the management of pain butab er a formulation of oral modified release buprenorphine for chronic pain and opioid dependence indications and mepi relmada therapeutics inc a clinical stage biotechnology company focuses on developing drugs to treat central nervous system cns diseases primarily depression and chronic pain in the united states its lead product candidate dmethadone is being developed as a rapidly acting oral agent for the treatment of depression neuropathic pain andor other potential cns pathological conditions the company is also developing include levocap er an extended release abuse deterrent proprietary formulation of the opioid analgesic levorphanol for the management of pain butab er a formulation of oral modified release buprenorphine for chronic pain and opioid dependence indications and mepigel a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies such as painful diabetic neuropathy postherpetic neuralgia and painful hivassociated neuropathy relmada therapeutics inc was founded in  and is based in new york new york detailed description  third avenueth floornew york ny united statesfounded in  employees wwwrelmadacom key executives for relmada therapeutics inc dr sergio traversa pharmd mba ceo interim cfo principal accounting officer  director age  total annual compensation k dr richard m mangano phd consultant age  total annual compensation k mr michael d becker consultant age  total annual compensation k compensation as of fiscal year  relmada therapeutics inc key developments relmada therapeutics inc appoints dr maurizio fava as chair of the dextromethadone scientific advisory board for its depression program jun   relmada therapeutics inc announced that dr maurizio fava has been named chair of the newly formed dextromethadone scientific advisory board of the company in this role dr fava will be a key advisor for the development program for dextromethadone rel  including preclinical and clinical research and regulatory strategies in coordination with relmadas established team of advisors and key opinion leaders dextromethadone is a novel nmethyldaspartate nmda receptor antagonist being developed as a rapidly acting oral agent for the treatment of depression and potentially other cns indications dr fava is director division of clinical research of the massachusetts general hospital mgh research institute executive vice chair of the mgh department of psychiatry and executive director of the mgh clinical trials network and institute and associate dean for clinical and translational research and slater family professor of psychiatry at harvard medical school relmada therapeutics inc announces appointments of dr ottavio vitolo as executive clinical advisor jun   relmada therapeutics inc announced that dr ottavio vitolo has been appointed executive clinical advisor to the company in this role dr vitolo will guide the clinical development program and preclinical research including trial design and execution for dextromethadone rel  a novel nmethyldaspartate nmda receptor antagonist being developed as rapidly acting oral agent for the treatment of depression and potentially other cns indications previously has held positions of increasing responsibility at pfizer including senior medical director and head of neuromuscular clinical research as well as head of implementation for rare neuromuscular disease programs targeting treatments for diseases including duchenne muscular dystrophy huntingtons disease and schizophrenia relmada therapeutics inc appoints charles j casamento as chairman of its board of directors jun   relmada therapeutics inc announced that charles j casamento has been appointed chairman of the companys board of directors mr casamento has been a member of the relmada therapeutics board of directors since july  and is also chairman of the audit committee and a member of the compensation and the corporate governance committees since  mr casamento has been executive director and principal of the sage group previously he was president and ceo of osteologix and founder chairman and ceo of questcor pharmaceuticals he also served as president ceo and chairman of ribogene inc and was cofounder president and ceo of indevus he has also held senior management positions at genzyme corporation american hospital supply johnson  johnson hoffmannlaroche and sandoz he has served as a director of eleven other pharmaceuticalbiotechnology companies and has been on the board of two not for profit organizations similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact relmada therapeutics inc please visit wwwrelmadacom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close relmada therapeutics inc  product pipeline review   trends statistics segment and forecasts market size share analysis  market research store     gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  pharmaceuticals relmada therapeutics inc  product pipeline review   published oct  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample relmada therapeutics inc  product pipeline review   summary global markets direct’s ‘relmada therapeutics inc  product pipeline review  ’ provides an overview of the relmada therapeutics inc’s pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of relmada therapeutics inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of relmada therapeutics inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of relmada therapeutics inc’s human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the relmada therapeutics inc’s pipeline products reasons to buy  evaluate relmada therapeutics inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of relmada therapeutics inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the relmada therapeutics inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of relmada therapeutics inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of relmada therapeutics inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of relmada therapeutics inc and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  relmada therapeutics inc snapshot  relmada therapeutics inc overview  key information  key facts  relmada therapeutics inc  research and development overview  key therapeutic areas  relmada therapeutics inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  relmada therapeutics inc  pipeline products glance  relmada therapeutics inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  relmada therapeutics inc  early stage pipeline products  preclinical productscombination treatment modalities  relmada therapeutics inc  drug profiles  levorphanol tartrate er  product description  mechanism of action  rd progress  buprenorphine hydrochloride er  product description  mechanism of action  rd progress  rel  product description  mechanism of action  rd progress  mepivacaine hydrochloride  product description  mechanism of action  rd progress  relmada therapeutics inc  pipeline analysis  relmada therapeutics inc  pipeline products by target  relmada therapeutics inc  pipeline products by route of administration  relmada therapeutics inc  pipeline products by molecule type  relmada therapeutics inc  pipeline products by mechanism of action  relmada therapeutics inc  recent pipeline updates  relmada therapeutics inc  dormant projects  relmada therapeutics inc  locations and subsidiaries  head office  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables relmada therapeutics inc key information  relmada therapeutics inc key facts  relmada therapeutics inc  pipeline by indication   relmada therapeutics inc  pipeline by stage of development   relmada therapeutics inc  monotherapy products in pipeline   relmada therapeutics inc  phase ii   relmada therapeutics inc  phase i   relmada therapeutics inc  preclinical   relmada therapeutics inc  pipeline by target   relmada therapeutics inc  pipeline by route of administration   relmada therapeutics inc  pipeline by molecule type   relmada therapeutics inc  pipeline products by mechanism of action   relmada therapeutics inc  recent pipeline updates   relmada therapeutics inc  dormant developmental projects  list of figures relmada therapeutics inc  pipeline by top  indication   relmada therapeutics inc  pipeline by stage of development   relmada therapeutics inc  monotherapy products in pipeline   relmada therapeutics inc  pipeline by top  target   relmada therapeutics inc  pipeline by top  route of administration   relmada therapeutics inc  pipeline by top  molecule type   relmada therapeutics inc  pipeline products by top  mechanism of action   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports life science analytics  global market outlook  jun  stratistics mrc  pages    code  mrs   according to stratistics mrc the global life science analytics market is expected to grow from  billion in  to reach  billion by  with a cagr of  some of the factors propelling the market growth are raising demand for analytics in sales and marketing applications increasing need of these solutions especially in clinical trials and improvements in technological advancements however lack of skilled professionals huge implementation costs and financial limitations read more chronic kidney disease ckd drugs  global market outlook  jul  stratistics mrc  pages    code  mrs   according to stratistics mrc the global chronic kidney disease ckd drugs market is expected to grow from  billion in  to reach  billion by  with a cagr of  drivers that are shaping the global market include growing incidences of chronic kidney diseases rise in aged population rising incidence of diabetes and obesity related disorders significant unmet requirements and beneficial reimbursement policies on the other hand factors such as intense competition fr read more acaricides  global market outlook  jul  stratistics mrc  pages    code  mrs   according to stratistics mrc the global acaricides market is expected to grow from  million in  to reach  million by  with a cagr of  high demand for meat dairy products and crops growth in crop protection industry and rise in productivity are some of the factors propelling the market growth however increase in cost alternative acaricides sources and regulatory restrictions are the factors suppressing the market on the other hand expansion of bioactive aca read more global and united states bacillus subtilis depth research report  jul  united states research  pages    code  mrs   this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a depth research report it covers all details inside analysis and opinion in bacillus subtilis industry this report focus united states market it covers details players regions product type and other details as following major companies bayer germany basf germany tonglu huifeng china kernel biotech china w read more global bacterial vaginosis drug market rport  jun  bisreport  pages    code  mrs   global bacterial vaginosis drug market report  full report  multi license section  section price as below page  chart and figure  publisher bisreport delivery time  hour contact salesbisreportcom phone  with the slowdown in world economic growth the bacterial vaginosis drug industry has also suffered a certain impact but still maintained a relatively optimistic growth the past four years bacterial vaginosis drug market size to maintain read more global alzheimers disease drug market rport  jun  bisreport  pages    code  mrs   global alzheimer’s disease drug market report  full report  multi license section  section price as below page  chart and figure  publisher bisreport delivery time  hour contact salesbisreportcom phone  with the slowdown in world economic growth the alzheimer’s disease drug industry has also suffered a certain impact but still maintained a relatively optimistic growth the past four years alzheimer’s disease drug market size to maintain read more global protein powder detailed analysis report  jul  detailed analysis research  pages    code  mrs   this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a detailed analysis report it covers all details inside analysis and opinion in protein powder industry this report splits protein powder market price size first speciality second speciality protein powder flavors which covers the history data information from  to  and forecast from  to  this report focus glob read more opioidinduced constipation oic  pipeline review h  jul  global markets direct  pages    code  mrs   opioidinduced constipation oic  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide opioidinduced constipation oic  pipeline review h  provides an overview of the opioidinduced constipation oic toxicology pipeline landscape opioids are effective pain relievers but often have the side effect of constipation these medicines affect the gastrointestinal tract in a variety of ways opioids increase the amo read more chemotherapy induced neutropenia  pipeline review h  jul  global markets direct  pages    code  mrs   chemotherapy induced neutropenia  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide chemotherapy induced neutropenia  pipeline review h  provides an overview of the chemotherapy induced neutropenia toxicology pipeline landscape chemotherapyinduced neutropenia is a very common side effect of cancer treatment symptoms include severe fatigue weakness anxiety lack of energy shortness of breath headaches pa read more chemotherapy induced nausea and vomiting  pipeline review h  jul  global markets direct  pages    code  mrs   chemotherapy induced nausea and vomiting  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide chemotherapy induced nausea and vomiting  pipeline review h  provides an overview of the chemotherapy induced nausea and vomiting toxicology pipeline landscape chemotherapy induced nausea and vomiting or cinv is nausea and vomiting that results specifically from treatment with chemotherapy drugs symptoms include a rapi read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports